Medtronic Stock

$90.28

0.74% today

NYSE, Jul 21, 06:45 pm CET

ISIN

IE00BTN1Y115

Symbol

MDT

Reports

Quarter | Annual

Index

NYSE Composite, S&P 500

Sector

Health

Industry

Medical specialties

Overview Dividends Analysts Charts News Strategies

Medtronic Stock price

$89.61

-6.12 6.39% 5Y

NYSE, Closing price Fri, Jul 18 2025

+0.08 0.09%

ISIN

IE00BTN1Y115

Symbol

MDT

Reports

Quarter | Annual

Index

NYSE Composite, S&P 500

Sector

Health

Industry

Medical specialties

Key metrics

Basic

Market capitalization

$114.8b

Enterprise Value

$134.4b

Net debt

$19.6b

Cash

$9.0b

Shares outstanding

1.3b

Valuation (TTM | estimate)

P/E

24.8 | 16.0

P/S

3.4 | 3.2

EV/Sales

4.0 | 3.8

EV/FCF

25.9

P/B

2.4

Dividends

DPS

$2.80

Yield 1Y | 5Y

3.1% | 2.7%

Growth 1Y | 5Y

1.4% | 5.3%

Payout 1Y | 3Y

77.6% | 90.1%

Increased

25 Years

Financials (TTM | estimate)

Revenue

$33.5b | $35.7b

EBITDA

$8.4b | $10.5b

EBIT

$6.6b | $9.0b

Net Income

$4.7b | $7.2b

Free Cash Flow

$5.2b

Growth (TTM | estimate)

Revenue

3.6% | 6.3%

EBITDA

8.1% | 22.9%

EBIT

8.5% | 34.4%

Net Income

26.8% | 54.2%

Free Cash Flow

-0.3%

Financial Health

Equity Ratio

52.4%

Return on Equity

9.7%

ROCE

8.4%

ROIC

7.0%

Debt/Equity

0.6

EPS

$3.6

FCF per Share

$4.0

Short interest

0.7%

Employees

95k

Rev per Employee

$350.0k

As a Free StocksGuide user, you can view scores for all 7,010 stocks worldwide.

Get Started for Free Today

Medtronic Stock Analysis

Unlock Scores for Free

??

39 Analysts have issued a Medtronic forecast:

21x Buy

54%

17x Hold

44%

More details on Analyst Estimates Including Price Targets

39 Analysts have issued a Medtronic forecast:

Buy

54%

Hold

44%

Sell

Analyst Estimates with Stock Price Targets

Financial data from Medtronic

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Apr '25		+/- %
Revenue	33,537 33,537	4% 4% 100%
- Direct Costs	11,576 11,576	4% 4% 35%
Gross Profit	21,961 21,961	3% 3% 65%
- Selling and Administrative Expenses	10,818 10,818	2% 2% 32%
- Research and Development Expense	2,718 2,718	1% 1% 8%
EBITDA	8,449 8,449	8% 8% 25%
- Depreciation and Amortization	1,807 1,807	7% 7% 5%
EBIT (Operating Income) EBIT	6,642 6,642	9% 9% 20%
Net Profit	4,663 4,663	27% 27% 14%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Medtronic Stock News

Neutral

PRNewsWire

●

about 5 hours ago

Medtronic secures CE Mark for MiniMed™ 780G System for insulin-requiring people with diabetes including expanded indications in children as young as two, during pregnancy, and for type 2 diabetes

GALWAY, Ireland , July 21, 2025 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in medical technology, today announced CE (Conformité Européenne) Mark in Europe to expand indications of the MiniMed™ 780G system for use by individuals aged 2 years and older, during pregnancy, as well as type 2 insulin-requiring diabetes. To gain CE Mark for this expansion of indications, published cli...

Positive

The Motley Fool

●

one day ago

10 Magnificent S&P 500 Dividend Stocks Down Over 10% to Buy and Hold Forever

Dividend stocks are one of the most powerful wealth compounders. The S&P 500 (SNPINDEX: ^GSPC) index offers the perfect example.

Neutral

The Motley Fool

●

2 days ago

Got $200? 2 Dividend Stocks to Buy and Hold Forever

The science that backs healthcare breakthroughs is mind-bogglingly complex. If you don't specialize in the medical space, you should probably avoid small, research-driven healthcare stocks.

More Medtronic News

Company Profile

Medtronic Plc is a medical technology company, which engages in the development, manufacture, distribution, and sale of device-based medical therapies and services. It operates through the following segments: Cardiac and Vascular Group; Minimally Invasive Technologies Group; Restorative Therapies Group; and Diabetes Group. The Cardiac and Vascular Group segment consist Cardiac Rhythm and Heart Failure, Coronary and Structural Heart, and Aortic and Peripheral Vascular divisions. The Minimally Invasive Technologies Group segment comprises Surgical Innovations and Respiratory, Gastrointestinal, and Renal divisions. The Restorative Therapies Group contains Spine, Brain, Specialty Therapies, and Pain Therapies divisions. The Diabetes Group segment focuses in the development, manufacturing, and marketing of products and services for the management of Type I and Type II diabetes. The company was founded in 1949 and is headquartered in Dublin, Ireland.

Head office	United States
CEO	Geoffrey Martha
Employees	95,000
Founded	2014
Website	www.medtronic.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now